Intech Investment Management LLC Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Intech Investment Management LLC increased its position in Hologic, Inc. (NASDAQ:HOLX) by 48.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,486 shares of the medical equipment provider’s stock after buying an additional 19,799 shares during the quarter. Intech Investment Management LLC’s holdings in Hologic were worth $4,491,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Cetera Investment Advisers raised its holdings in shares of Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after purchasing an additional 13,380 shares during the period. Nordea Investment Management AB lifted its position in Hologic by 1.3% during the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after buying an additional 19,680 shares in the last quarter. Pinebridge Investments L.P. grew its stake in Hologic by 39.8% during the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after buying an additional 113,050 shares during the period. Clearbridge Investments LLC increased its position in shares of Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock worth $40,430,000 after acquiring an additional 176,006 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Hologic by 18.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after acquiring an additional 338,212 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 1.2 %

NASDAQ HOLX opened at $81.39 on Friday. The company has a market capitalization of $18.99 billion, a price-to-earnings ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company’s fifty day moving average price is $80.82 and its two-hundred day moving average price is $77.12.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.93 earnings per share. As a group, research analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. JPMorgan Chase & Co. raised their target price on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Tuesday, September 17th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Activity

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.